Taldefgrobep alfa – Biohaven

Taldefgrobep alfa is an anti-myostatin, which means it targets myostatin, a natural protein that is important in healthy muscular development. In people with neuromuscular diseases, active myostatin can limit the skeletal muscle growth needed to achieve developmental and functional milestones. Taldefgropep alfa is designed to increase muscle mass and strength in SMA patients via dual inhibition functioning, by directly lowering myostatin levels and blocking myostatin function.

Method of Action

Trials of taldefgrobep alfa

Regulatory:
<ul>
<li>February 2023: <a href="https://ir.biohaven.com/news-releases/news-release-details/biohavens-taldefgrobep-alfa-receives-fda-fast-track-designation" target="_blank" rel="noopener">taldefgrobep alfa receives FDA ffast-track designation for spinal muscular atrophy patients in addition to previously receiving orphan drug designation in the US.</a></li>
<li>October 2023: <a href="https://ir.biohaven.com/news-releases/news-release-details/biohaven-completes-enrollment-pivotal-phase-3-study-taldefgrobep" target="_blank" rel="noopener">Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy</a></li>
</ul>